Moleculin Biotech (MBRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MBRX Moleculin Biotech

Watchlist

2.5900
+0.3200+14.10%

Close Aug 2 16:00 ET

2.5500
-0.0400-1.54%

Post 20:01 ET

6.63MMarket Cap-199P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Buy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued Shares
TipRanksAug 2 14:25 ET · Ratings
Moleculin Biotech Advances to Phase 3 in AML Treatment Trial
TipRanksAug 1 09:01 ET
Moleculin Biotech Unveils Corporate Strategy Update Presentation
TipRanksAug 1 09:00 ET
Moleculin Announces Plans For MIRACLE Adaptive Phase 3 Clinical Trial Designed For Possible Accelerated Approval Of Annamycin In Combination With Cytarabine For The Treatment Of Relapsed Or Refractory AML
BenzingaAug 1 08:36 ET
Express News | Moleculin Announces Plans for Miracle Phase 3 Pivotal Trial
ReutersAug 1 08:30 ET
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
Moleculin BiotechAug 1 00:00 ET

Comments

Jaguar8

Jul 10 07:34

NEWS

$Moleculin Biotech(MBRX.US)$
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Moleculin Biotech has completed its End of Phase 2 (EOP2) meeting with the FDA for its Phase 1B/2 clinical trial of Annamycin combined with Cytarabine for treating AML (MB-106). The meeting focused on reviewing clinical data and planning the next steps, with official outcomes expected by Q3 2024. Interim results show that out of 22 enrolled subjects, 45% achieved a composite complete remiss...

Trytosaveabit

Jun 14 07:03

Update

$Moleculin Biotech(MBRX.US)$ Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial! 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study! Annamycin Continues to Demonstrate No Cardiotoxicity! Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study

Mcsnacks H Tupack

Jun 8 02:59

Mixed shelf offering

$Moleculin Biotech(MBRX.US)$ Means the stock will go on a run soon which will then be stopped by adding shares. If you buy you might wanf try to sell before it reaches 30% gains.

Trytosaveabit

May 15 07:57

Update

$Moleculin Biotech(MBRX.US)$ Moleculin Announces Commencement of Nih-Funded Phase 2 Clinical Trial of Stat3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)